1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. SLEEP DISORDER TREATMENT MARKET BY DRUG TYPE
5.1. Introduction
5.2. Benzodiazepines
5.3. Nonbenzodiazepines
5.4. Antidepressants
5.5. Orexin Antagonists
5.6. Melatonin Antagonists
5.7. Other Drug Types
6. SLEEP DISORDER TREATMENT MARKET BY APPLICATION
6.1. Introduction
6.2. Insomnia
6.3. Sleep Apnea
6.4. Narcolepsy
6.5. Circadian Disorders
6.6. Other Applications
7. SLEEP DISORDER TREATMENT MARKET BY PAYOR
7.1. Introduction
7.2. Public Health Insurance
7.3. Private Health Insurance
8. SLEEP DISORDER TREATMENT MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Dr Reddy's Laboratory
10.2. Merck & Co.
10.3. Pfizer
10.4. Sanofi SA
10.5. Takeda Pharmaceuticals Inc.
10.6. Teva Pharmaceuticals Inc.
10.7. Vanda Pharmaceuticals Inc.
10.8. Sleep Health Solutions
10.9. Cleveland Clinic
10.10. Mayo Clinic
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES